Table 3.

Subgroup analyses for the absolute change in LDL-C from baseline to 8 weeks.

	Evolocumab		SOC		Mean difference (95% CI)	p a	Interaction pb
	n = 59	Mean ± SD	n = 60	Mean ± SD
Age							0.148
<65 years	41	−2.28 ± 0.96	31	−0.65 ± 0.94	−1.64 (−2.09 to −1.19)	<0.001
≥65 years	18	−2.42 ± 0.84	29	−1.27 ± 0.74	−1.14 (−1.61 to −0.67)	<0.001
Gender							0.803
Male	45	−2.31 ± 0.96	38	−0.97 ± 0.96	−1.34 (−1.76 to −0.93)	<0.001
Female	14	−2.36 ± 0.82	22	−0.92 ± 0.80	−1.44 (−2.00 to −0.87)	<0.001
Statin history							0.842
Yes	6	−2.14 ± 0.68	3	−0.62 ± 1.25	−1.51 (−2.99 to −0.04)	0.046
No	53	−2.34 ± 0.95	57	−0.97 ± 0.89	−1.38 (−1.72 to −1.03)	<0.001
LDL-C at baseline							0.209
<The median	32	−1.73 ± 0.55	27	−0.42 ± 0.58	−1.31 (−1.61 to −1.02)	<0.001
≥The median	27	−3.03 ± 0.76	33	−1.39 ± 0.88	−1.64 (−2.08 to −1.21)	<0.001

SOC, standard of care; CI, confidence interval; LDL-C, low-density lipoprotein cholesterol.

^a t-test.

^bMultivariate analysis of variance.